Positioning statement. This paper does not argue that vitamin C is an established treatment for borderline personality disorder. It presents a mechanistically grounded but clinically unproven hypothesis and proposes a specific pilot trial to test it. The paper is meant as an invitation to empirical examination, not as a claim that efficacy is already known.

Ascorbic Acid as a Potential Adjunctive Intervention in Borderline Personality Disorder: A Mechanistic Hypothesis and Rationale for a Pilot Trial

Narrative, hypothesis-generating overview

[Authors]   [Affiliations]   [Corresponding author]

Abstract

Borderline personality disorder (BPD) is characterized by affective instability, impulsivity, interpersonal dysfunction, and marked stress reactivity. Psychotherapy, especially dialectical behavior therapy (DBT), remains the treatment cornerstone, while adjunctive biological interventions have a comparatively limited evidence base. This narrative, hypothesis-generating overview examines whether ascorbic acid (vitamin C) deserves empirical study as an adjunctive intervention in BPD. The rationale is mechanistic rather than evidentiary. Vitamin C is an established cofactor for dopamine-β-hydroxylase (DβH), supports tetrahydrobiopterin (BH4)-dependent monoamine synthesis, and modulates glutamatergic NMDA-related signaling. These pathways intersect conceptually with aspects of BPD neurobiology involving emotional dysregulation, frontolimbic dysfunction, stress sensitivity, and possible catecholaminergic involvement. At the same time, several counterarguments substantially limit the hypothesis: catecholamine findings in BPD are inconsistent; Friedel's dopamine model was explicitly presented as circumstantial; meta-analytic evidence for vitamin C in mood is mixed (Hedge's g=0.09, N=836, n.s.); and brain ascorbate homeostasis may limit the impact of oral supplementation in replete individuals. Accordingly, this paper does not argue that vitamin C is likely to treat BPD. Rather, it proposes that vitamin C is a low-cost, biologically plausible, and testable candidate for preliminary evaluation. A randomized, double-blind, placebo-controlled pilot trial is outlined (N=80; 24 weeks; vitamin C 1,000 mg/day vs. placebo as add-on to DBT), with the Borderline Symptom List-23 (BSL-23) as the primary outcome and plasma ascorbate, homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) as exploratory biomarkers. This is an invitation to empirical testing, not a claim that therapeutic efficacy is established.

Keywords: borderline personality disorder; ascorbic acid; vitamin C; catecholamines; dopamine-β-hydroxylase; tetrahydrobiopterin; NMDA; dialectical behavior therapy; pilot trial

1. Introduction

Borderline personality disorder is a severe psychiatric condition characterized by affective lability, impulsive self-damaging behavior, unstable attachment, chronic emptiness, anger dyscontrol, and heightened reactivity to interpersonal stress. It affects an estimated 1–2% of the general population and up to 20% of psychiatric inpatients, with lifetime suicide rates of 8–10% (Leichsenring et al., 2011; Paris, 2019). Across current treatment frameworks, structured psychotherapy remains the central intervention, with DBT among the most empirically supported approaches (Storebø et al., 2020). Pharmacotherapy has a more limited and symptom-targeted role; no medication carries regulatory approval for BPD, and a Cochrane review concluded that the evidence for any pharmacological agent is of low to very low quality (Stoffers-Winterling et al., 2022).

Nutritional supplementation has received minimal attention. Only omega-3 fatty acids have been tested in replicated trials, yielding a pooled effect size of d=0.54 for overall BPD symptom severity across four RCTs totaling 137 patients (Karaszewska et al., 2021). No study has examined vitamin C in BPD or in any personality disorder.

The present paper is intentionally **not** a systematic review. It is a narrative, hypothesis-generating overview that asks whether a specific biochemical fact pattern justifies a pilot trial. Vitamin C has well-established roles in catecholamine and monoamine-related neurochemistry, while parts of BPD neurobiology may involve dysregulation in those same systems. The purpose is not to infer efficacy from mechanism, but to determine whether a cautious translational hypothesis is sufficiently plausible to test.

2. Why Consider Vitamin C in BPD?

The starting point is not that BPD is a “vitamin deficiency disorder,” nor that catecholamine dysfunction has been conclusively demonstrated in BPD. The case depends on convergence across several weaker-to-moderate evidence strands rather than on any single decisive finding.

3. BPD Neurobiology: What Is Actually Known?

3.1 Serotonergic findings are stronger than catecholaminergic findings

The best-established neurotransmitter findings in BPD concern serotonin. Reduced CSF 5-HIAA, blunted prolactin responses to fenfluramine (Coccaro et al., 1989; Soloff et al., 2000), and PET evidence of decreased serotonin synthesis capacity in corticostriatal circuits (Leyton et al., 2001; N=13 BPD vs. 11 controls) have been replicated across independent groups. TPH2 gene variants associate with affective lability independent of aggression (Gutknecht et al., 2007; Perez-Rodriguez et al., 2010). **Evidence strength: strong.** This matters because any catecholamine-based vitamin C hypothesis should not replace the serotonin literature. At most, the BH4-related mechanism discussed below suggests a possible bridge between catecholaminergic and serotonergic physiology.

3.2 Dopamine: plausible, but still indirect

Friedel's (2004) influential hypothesis proposed that dopaminergic dysfunction could contribute to emotional dysregulation, impulsivity, and cognitive-perceptual symptoms, but he stated clearly that the evidence was *circumstantial*. That caution must be preserved, not softened. Still, some data are worth noting. Tadić et al. (2009) reported overrepresentation of the COMT Met158Met genotype in BPD (N=161 vs. 156 controls; p=0.0085). Joyce et al. (2006) reported DAT1-related risk estimates in the range of OR=2.67–3.67. Hess et al. (2009) examined DBH-related impulsive personality traits in a combined sample of N=1,613, supporting the broader relevance of catecholamine-related genes to impulsivity-associated phenotypes. These findings are not definitive evidence of dopamine dysfunction in BPD, but they indicate that catecholaminergic biology is not an unreasonable place to look. **Evidence strength: moderate.**

3.3 Norepinephrine: sparse and internally contradictory

The noradrenergic literature is weaker and more problematic. Gardner et al. (1990) found no significant CSF differences in HVA or MHPG between BPD patients and controls. Coccaro et al. (2003) reported that plasma free MHPG correlated *inversely* with life history of aggression in personality-disordered subjects (N=30), whereas earlier central measures had suggested the opposite direction.

More importantly, Philipsen et al. (2004) found that **clonidine**—an alpha-2 adrenergic agonist that reduces noradrenergic firing—improved hyperarousal-related symptoms in women with BPD. This is an important counterargument. If reducing noradrenergic tone helps some BPD patients, one cannot simply assume that a nutrient participating in norepinephrine synthesis would be beneficial by increasing catecholamine output. The correct inference is not that vitamin C should help, but that catecholaminergic modulation in BPD is likely complex, state-dependent, and heterogeneous across patients. **Evidence strength: weak. This strand weakens rather than supports a simple "more norepinephrine" model.**

3.4 Frontolimbic dysfunction is robust, but not transmitter-specific

Functional imaging consistently implicates frontolimbic dysregulation in BPD, especially impaired prefrontal control over limbic reactivity (Schulze et al., 2016). The normal positive OFC-amygdala metabolic correlation present in controls is absent in BPD (New et al., 2007; N=26 vs. 24). These findings support the idea that biologically relevant adjuncts might influence emotion regulation circuitry, but they do not identify a single neurotransmitter lesion. **Evidence strength for PFC dysfunction: strong. For catecholaminergic specificity: moderate.**

4. Mechanism 1: Vitamin C as a Cofactor for Dopamine-β-Hydroxylase

Evidence strength: very strong biochemically; weak clinically in BPD.

Ascorbic acid is the obligatory electron donor for DβH, the enzyme converting dopamine to norepinephrine. This relationship, characterized since 1960 (Levin et al., 1960), has been confirmed in biochemical, vesicular, and neuronal systems. In SH-SY5Y neuroblastoma cells, norepinephrine synthesis was stimulated several-fold by intracellular ascorbate, with half-maximal effects at 0.2–0.5 mM—consistent with physiological intraneuronal concentrations achievable from extracellular ascorbate below 25 μM via SVCT2 concentrative transport (May et al., 2013). This is established enzymology, not speculation.

However, a true enzymatic role does **not** imply therapeutic relevance in BPD. The direction of noradrenergic dysfunction in BPD is not established, and the clonidine findings caution against simplistic “more norepinephrine is better” thinking. The DβH mechanism supports **plausibility**, not directional certainty.

5. Mechanism 2: Vitamin C, BH4 Recycling, and Monoamine Synthesis

Evidence strength: moderate-to-strong preclinical; indirect clinically.

Ascorbate helps maintain tetrahydrobiopterin (BH4), a critical cofactor for both tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes for catecholamine and serotonin synthesis respectively. Ascorbate reduces the trihydrobiopterin radical more efficiently than glutathione (May et al., 2012). SVCT2 knockout mice show ~33% reductions in cortical dopamine and norepinephrine with decreased tyrosine hydroxylase protein (Harrison et al., 2010). ODS rats (unable to synthesize ascorbate) show decreased brain BH4 with concurrent monoamine reductions (Nakanishi et al., 2019). At intracellular ascorbate above 1.5 mM, tyrosine hydroxylase expression itself increases (May et al., 2012).

This mechanism broadens the rationale in two ways. First, it extends beyond norepinephrine to dopamine and serotonin—important because serotonergic evidence in BPD is stronger than catecholaminergic evidence. Second, it allows a more nuanced hypothesis: any clinical effect, if present, may relate not to a single catecholamine increase, but to support of monoamine synthesis under biologically stressed or marginal conditions. Still, most evidence is preclinical. Human in vivo proof that ordinary oral vitamin C substantially shifts central BH4-dependent neurotransmission is lacking.

6. Mechanism 3: NMDA / Glutamatergic Modulation

Evidence strength: strong preclinical; weak-to-indirect clinically.

Ascorbate modulates NMDA receptor function through redox-sensitive cysteine residues and has shown neuroprotective effects in glutamatergic models (Majewska et al., 1990). Grosjean and Tsai (2007) proposed NMDA neurotransmission as a critical mediator of BPD. This mechanism broadens the rationale beyond catecholamine synthesis and suggests that vitamin C could, in theory, intersect with stress-sensitive excitatory signaling.

This mechanism should not be oversold. It does not show that vitamin C has ketamine-like clinical relevance in BPD, nor does it establish symptom-level efficacy. Its value is mainly that it broadens the biological rationale. No human study has demonstrated that vitamin C improves emotion regulation through NMDA-related pathways.

7. The Blood-Brain Constraint

The brain maintains ascorbate at 4–200 times plasma levels via SVCT2 active transport (Harrison & May, 2009). CSF concentrations plateau when plasma exceeds ~45 μmol/L; oral supplementation raises brain levels by only ~20% in replete individuals (Lykkesfeldt & Tveden-Nyborg, 2019). This is the main translational bottleneck.

The hypothesis is therefore more plausible if BPD patients have suboptimal vitamin C status. Indirect support exists: psychiatric inpatients commonly show mild deficiency (Bari et al., 2023), and BPD patients frequently exhibit smoking, chaotic eating, and substance use—all depletion risk factors. However, this has never been measured specifically in BPD. If patients are replete, the marginal benefit of supplementation may be negligible.

8. Clinical Psychiatric Evidence: Mixed and Incomplete

A meta-analysis of 10 RCTs (Yosaee et al., 2021; N=836) found no significant overall mood effect (Hedge's $g=0.09$, $p=0.465$), with a modest subgroup signal only in subclinical depression ($g=-0.18$, $p=0.041$). Individual trials are contradictory: Amr et al. (2013) found vitamin C

1,000 mg/day significantly augmented fluoxetine in pediatric MDD (N=24, 6 months, $p<0.0001$ on CDRS), while Sahraian et al. (2015) found no benefit added to citalopram in adult MDD (N=43, 8 weeks).

The most consistent signal concerns stress reactivity. Brody et al. (2002) demonstrated that 3,000 mg/day for 14 days produced lower systolic blood pressure responses, faster cortisol recovery, and reduced subjective stress during the Trier Social Stress Test (N=120, double-blind RCT). In a disorder as stress-reactive as BPD, that is conceptually relevant—but still far from proof of efficacy on core BPD symptoms.

Crucially, **no clinical evidence exists for vitamin C affecting impulsivity or emotion regulation**—the domains most central to BPD. This is not a small gap; it is the main reason this paper remains a hypothesis rather than a treatment argument.

9. The Major Counterarguments

9.1 Friedel’s dopamine model remains circumstantial

This is the most important conceptual restraint. The dopamine hypothesis in BPD remains influential because it is intellectually interesting, not because it has been directly confirmed. No honest rationale paper should write as if dopamine dysfunction in BPD were established fact.

9.2 The noradrenergic story is inconsistent, and clonidine is a real objection

The clonidine finding (Philipsen et al., 2004) points in the opposite direction from a simplistic catecholamine-enhancement model. If benefit occurs, it may come primarily through BH4-related serotonergic support or stress-buffering effects rather than norepinephrine enhancement.

9.3 The clinical vitamin C literature is mixed

Meta-analytic evidence for mood benefit is not robust (Yosaee et al., 2021; $g=0.09$, n.s.). BPD-relevant symptom domains—impulsivity, affective lability, interpersonal dysfunction—have not been tested.

9.4 Brain ascorbate homeostasis limits oral supplementation

Any signal may be strongest in participants with lower baseline status. In replete individuals, the effect may be negligible. This is precisely why a pilot study should measure plasma ascorbate and treat biomarker change as part of the question.

9.5 BPD should not be reduced to a nutritional lever

If vitamin C were ever to show benefit, it would most plausibly operate as a small adjunctive factor improving stress tolerance or treatment engagement—not as a standalone treatment. The omega-3 literature (d=0.54) provides a ceiling estimate for nutritional supplementation in BPD.

These objections do not invalidate the hypothesis. They define the standard it must meet.

10. Why a Pilot Trial Is Still Reasonable

Despite these objections, a pilot trial remains scientifically reasonable for five pragmatic reasons.

First, the mechanistic case is not a single weak chain but a convergence of three partially independent pathways: DβH cofactor activity, BH4-related monoamine support, and NMDA-related modulation.

Second, the intervention is low-cost, familiar, and operationally easy to study.

Third, BPD adjunct research is sparse. Omega-3 trials show that low-risk biological add-ons can be studied meaningfully in this population, even though that precedent does not validate vitamin C itself.

Fourth, DBT provides an ideal platform for an adjunctive trial because it is standardized and evidence-based. The translational question is not whether vitamin C can replace psychotherapy, but whether it can modestly improve outcomes when added to DBT.

Fifth, the study can be designed so that a negative result is still informative. If supplementation raises plasma ascorbate without improving symptoms, that argues against the translational significance of the proposed mechanisms at oral doses.

11. Hypothesis

We hypothesize that **ascorbic acid, when added to standard DBT, may produce a small but measurable improvement in overall BPD symptom severity in a subset of patients**, potentially through combined effects on DβH-dependent catecholamine synthesis, BH4-supported monoamine pathways, and glutamatergic NMDA-related modulation.

A secondary hypothesis is that any signal, if present, may be stronger in participants with lower baseline ascorbate status, smoking exposure, poorer diet quality, or greater stress-related symptom burden.

This is a **speculative, mechanism-led hypothesis**. It is offered as a basis for empirical testing, not as a conclusion.

12. Pilot Trial Proposal

12.1 Design

Table 1. *Proposed pilot trial design.*

Element	Specification
Design	Randomized, double-blind, placebo-controlled, parallel-group pilot trial at a single German DBT center.
Population	N=80 adults (18–55) meeting DSM-5 criteria for BPD and enrolled in standard DBT. Exclusions: nephrolithiasis, G6PD deficiency, hemochromatosis, severe hepatic/renal impairment.
Intervention	Ascorbic acid 1,000 mg/day (500 mg BID) vs. matched placebo for 24 weeks, both as add-on to DBT.
Primary outcome	Borderline Symptom List-23 (BSL-23; Bohus et al., 2009). Assessed at baseline, weeks 4, 8, 12, 16, 20, 24, and 3-month follow-up.
Secondary outcomes	Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004); Barratt Impulsiveness Scale-11 (BIS-11; Patton et al., 1995); PHQ-9; GAD-7; WHOQOL-BREF; self-harm frequency; treatment retention.
Safety monitoring	Columbia Suicide Severity Rating Scale (C-SSRS) at each visit; standard DBT crisis procedures including 24/7 phone coaching; clear discontinuation criteria.
Exploratory biomarkers	Plasma ascorbate, HVA, MHPG at baseline, week 12, week 24.
Analysis	Mixed-effects model for repeated measures (MMRM). Emphasis on feasibility, effect-size estimation with 95% CI, and confidence intervals per pilot methodology guidelines (Leon et al., 2011).
Ethics & registration	Ethics committee approval; DRKS registration; Probandenversicherung; extended informed consent with cooling-off period; GDPR/DSGVO compliance.

12.2 Biomarker Strategy

Plasma ascorbate serves primarily as a compliance and exposure marker. HVA and MHPG are exploratory rather than decisive: changes would not prove synaptic catecholamine normalization, but they could indicate whether the clinical hypothesis moves in the expected biological direction. If symptom change occurred without biomarker movement, the mechanistic interpretation would need to shift toward stress-buffering or glutamatergic pathways.

12.3 Feasibility, Cost, and Funding

Estimated total cost: €300,000–380,000, covering personnel, biomarker assays (~€48,000), vitamin C and placebo manufacture, ethics and insurance, and data management. Several German funding mechanisms are suitable for a trial at this scale:

DFG Clinical Trials Programme: accepts investigator-initiated applications year-round for trials in this budget range.

VolkswagenStiftung "Experiment!": specifically funds unconventional research ideas with up to €120,000 for 18 months.

Deutsches Zentrum für Psychische Gesundheit (DZPG): established 2023 by the BMBF, with a site at the Central Institute of Mental Health in Mannheim—where the BSL-23 was developed—representing an ideal institutional partner.

The trial's low substance cost and use of existing DBT infrastructure make it unusually cost-effective relative to pharmaceutical RCTs.

13. Interpreting Positive and Negative Results

A positive pilot result would **not** show that vitamin C "treats BPD." At most, it would justify a larger, stratified trial with attention to baseline ascorbate status, smoking, diet, and symptom subtypes (hyperarousal vs. impulsive dyscontrol vs. affective instability). The biomarker panel would help test whether any clinical signal tracks with catecholamine-metabolite shifts or with nutritional correction.

A negative result would be equally informative. If supplementation reliably raises plasma ascorbate without changing symptoms, that argues against the translational relevance of the proposed mechanisms at ordinary oral doses. If plasma ascorbate does not rise (indicating non-compliance or malabsorption), the trial would be uninformative about the hypothesis but informative about feasibility. Either outcome sharpens the field.

14. Conclusion

Ascorbic acid is a biologically credible but clinically unproven candidate adjunctive intervention in BPD. The rationale rests on three converging mechanisms: a very strong biochemical role as a DβH cofactor, a moderate-to-strong preclinical role in BH4-dependent monoamine synthesis engaging both catecholamine and serotonin pathways, and a strong preclinical but clinically unvalidated role in NMDA modulation. Against this stand serious limitations: catecholamine dysfunction in BPD is not directly established; noradrenergic findings are inconsistent and clonidine provides a genuine counter-signal; oral supplementation may have limited impact on brain ascorbate in replete individuals; and the human psychiatric intervention literature is mixed.

What justifies pursuing the idea is not certainty, but testability combined with an exceptionally favorable cost-risk ratio and a clinical population with few validated adjunctive options. A small, well-designed pilot could determine whether the hypothesis deserves to be abandoned or pursued further.

This paper is an invitation to test an idea, not a claim that the idea is correct.

References

Amr M, El-Mogy A, Shams T, Viber K, Courtney D. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutr J. 2013;12:31. doi:10.1186/1475-2891-12-31

Bari V, Bhulani N, Asghar M, Ali A. Mild vitamin C deficiency is common in the inpatient psychiatric setting. J Clin Psychiatry. 2023;84(5):23m14909. doi:10.4088/JCP.23m14909

Bohus M, Kleindienst N, Limberger MF, et al. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology. 2009;42(1):32–39. doi:10.1159/000173701

Brody S, Preut R, Schommer K, Schürmeyer TH. A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress. Psychopharmacology (Berl). 2002;159(3):319–324. doi:10.1007/s00213-001-0929-6

Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry. 1989;46(7):587–599. doi:10.1001/archpsyc.1989.01810070013002

Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL. Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectr. 2003;8(10):731–736. doi:10.1017/S1092852900019106

Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004;29(6):1029–1039. doi:10.1038/sj.npp.1300424

Gardner DL, Lucas PB, Cowdry RW. CSF metabolites in borderline personality disorder compared with normal controls. Biol Psychiatry. 1990;28(3):247–254. doi:10.1016/0006-3223(90)90504-M

Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation. J Psychopathol Behav Assess. 2004;26(1):41–54. doi:10.1023/B:JOBA.0000007455.08539.94

Grosjean B, Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci. 2007;32(2):103–115.

Gutknecht L, Jacob C, Strobel A, et al. Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. Int J Neuropsychopharmacol. 2007;10(3):309–320. doi:10.1017/S1461145706007266

Harrison FE, Dawes SM, Meredith ME, et al. Low vitamin C and increased oxidative stress and cell death in mice that lack SVCT2. Free Radic Biol Med. 2010;49(5):821–829. doi:10.1016/j.freeradbiomed.2010.06.008

Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med. 2009;46(6):719–730. doi:10.1016/j.freeradbiomed.2008.12.018

Hess C, Reif A, Strobel A, et al. A functional dopamine-β-hydroxylase gene promoter polymorphism is associated with impulsive personality styles. J Neural Transm. 2009;116(2):121–130. doi:10.1007/s00702-008-0148-1

Joyce PR, McHugh PC, McKenzie JM, et al. A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients. Psychol Med. 2006;36(6):807–813. doi:10.1017/S0033291706007288

Karaszewska DM, Ingenhoven T, Mocking RJT. Marine omega-3 fatty acid supplementation for borderline personality disorder: a meta-analysis. J Clin Psychiatry. 2021;82(3):20r13613. doi:10.4088/JCP.20r13613

Kleindienst N, Jungkunz M, Bohus M. A proposed severity classification of borderline symptoms using the BSL-23. Borderline Personal Disord Emot Dysregul. 2020;7:19. doi:10.1186/s40479-020-00126-6

Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2011;377(9759):74–84. doi:10.1016/S0140-6736(10)61422-5

Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626–629. doi:10.1016/j.jpsychires.2010.10.008

Levin EY, Levenberg B, Kaufman S. The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J Biol Chem. 1960;235:2080–2086.

Leyton M, Okazawa H, Diksic M, et al. Brain regional α-[11C]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry. 2001;158(5):775–782. doi:10.1176/appi.ajp.158.5.775

Lykkesfeldt J, Tveden-Nyborg P. The pharmacokinetics of vitamin C. Nutrients. 2019;11(10):2412. doi:10.3390/nu11102412

Majewska MD, Bell JA, London ED. Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate. Brain Res. 1990;537(1–2):328–332. doi:10.1016/0006-8993(90)90379-P

May JM, Qu ZC, Nazarewicz R, Dikalov S. Ascorbic acid efficiently enhances neuronal synthesis of norepinephrine from dopamine. Brain Res Bull. 2013;90:35–42. doi:10.1016/j.brainresbull.2012.09.009

May JM, Qu ZC, Meredith ME. Mechanisms of ascorbic acid stimulation of norepinephrine synthesis in neuronal cells. Biochem Biophys Res Commun. 2012;426(1):148–152. doi:10.1016/j.bbrc.2012.08.054

Moretti M, Budni J, Freitas AE, et al. Ascorbic acid to manage psychiatric disorders. CNS Drugs. 2017;31(7):571–583. doi:10.1007/s40263-017-0446-8

Nakanishi N, et al. Deficiency of ascorbic acid decreases the contents of tetrahydrobiopterin in the liver and brain of ODS rats. Neurosci Lett. 2019;715:134656. doi:10.1016/j.neulet.2019.134656

New AS, Hazlett EA, Buchsbaum MS, et al. Amygdala-prefrontal disconnection in borderline personality disorder. Neuropsychopharmacology. 2007;32(7):1629–1640. doi:10.1038/sj.npp.1301283

Paris J. Suicidality in borderline personality disorder. Medicina (Kaunas). 2019;55(6):223. doi:10.3390/medicina55060223

Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768–774. doi:10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1

Perez-Rodriguez MM, Weinstein S, New AS, et al. TPH2 haplotype association with borderline personality disorder and aggression. J Psychiatr Res. 2010;44(15):1075–1081. doi:10.1016/j.jpsychires.2010.04.014

Philipsen A, Richter H, Schmahl C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004;65(10):1414–1419. doi:10.4088/JCP.v65n1018

Plevin D, Galletly C. The neuropsychiatric effects of vitamin C deficiency: a systematic review. BMC Psychiatry. 2020;20(1):315. doi:10.1186/s12888-020-02730-w

Sahraian A, Ghanizadeh A, Kazemi F. Vitamin C as an adjuvant for treating major depressive disorder and suicidal behavior. Trials. 2015;16:94. doi:10.1186/s13063-015-0609-1

Schulze L, Schmahl C, Niedtfeld I. Neural correlates of disturbed emotion processing in borderline personality disorder: a multimodal meta-analysis. Biol Psychiatry. 2016;79(2):97–106. doi:10.1016/j.biopsych.2015.02.013

Soloff PH, Meltzer CC, Greer PJ, et al. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry. 2000;47(6):540–547. doi:10.1016/S0006-3223(99)00202-4

Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5:CD012955. doi:10.1002/14651858.CD012955.pub2

Stoffers-Winterling JM, Storebø OJ, Kongerslev MT, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022;11:CD012956. doi:10.1002/14651858.CD012956.pub2

Tadić A, Victor A, Baskaya O, et al. Interaction between 5-HTTLPR and COMT in borderline personality disorder. Am J Med Genet B. 2009;150B(4):487–495. doi:10.1002/ajmg.b.30847

Yosaee S, Clark CCT, Keshtkar A, et al. The effect of vitamin C supplementation on mood status in adults: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2021;71:36–42. doi:10.1016/j.genhosppsych.2021.04.006